IQVIA Biotech’s Megan Hooton, IQVIA Institute's Murray Aitken and IQVIA's Keith McDonald as they discuss the importance of innovative trial designs in accelerating R&D processes to reduce development timelines. Register today to hear their insights in full.https://lnkd.in/eVySuVsG
Speaker Profiles
Meg HootonPresidentIQVIA BiotechMegan Hooton, President of IQVIA Biotech, leads the strategic direction of global business, ensuring successful project delivery across all Biotech and MedTech clinical trials. With over three decades of experience in managing global research and development, Meg provides oversight to clinical teams, investigator site services, data services and therapeutic divisions. Her remarkable journey—from nursing to biotech leadership—reflects not only her wealth of operational insights but also her cross-cultural expertise and unwavering commitment to advancing healthcare.LinkedIn: https://www.linkedin.com/in/meganhooton/
Murray AitkenExecutive DirectorIQVIA Institute for Human Data ScienceMurray Aitken, the Executive Director of the IQVIA Institute for Human Data Science, is a globally recognized authority in addressing challenges within the healthcare industry. With a rich 15-year history at IQVIA, he has seamlessly navigated diverse roles spanning healthcare insights, corporate strategy and consulting. Previously, he was a partner at McKinsey & Company in the US and South Korea, for which he focused heavily on Life Sciences. Murray earned his MBA from Harvard and a Masters of Commerce from the University of Auckland. He is a sought-after speaker at international healthcare forums. His insightful perspectives grace esteemed publications including The Wall Street Journal, The Financial Times, Fortune and CNBC.LinkedIn: https://www.linkedin.com/in/murray-aitken-iqviainstitute/ Keith McDonaldHead of Drug Development Strategy, Regulatory Affairs & Drug Development SolutionsIQVIAKeith McDonald, a seasoned expert with over 25 years in regulatory affairs and drug development, leads as the Head of Drug Development Strategy at IQVIA. His extensive regulatory authority expertise in clinical trials, marketing authorization approvals and policy development makes him an authority in our industry. His many contributions include providing regulatory authority scientific advice to leading the UK Covid Therapeutics Taskforce, where he shaped policy and secures marketing authorizations.LinkedIn: https://www.linkedin.com/in/keith-mcdonald-287543a2/
info@wilam.comAn initiative ofBioMelbourne NetworkLevel 6, HWT Tower40 City RoadSouthbank, VIC 3006
Wilam means home in the Woi-wurrung language of the Wurundjeri People of the Kulin Nation, the Traditional Owners of the lands on which we are based.We respectfully acknowledge the Traditional Custodians of the unceded lands and waters of Victoria, the Bunurong, Eastern Maar, Gunaikurnai, Wadawurrung and Wurundjeri Woi-wurrung peoples, on which we live and work. We pay respect to their Elders past and present. We acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector. We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.